SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Provectus Pharmaceuticals Inc.
PVCT 0.0650+0.2%12:36 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Howard Williams6/5/2013 7:15:11 AM
1 Recommendation

Recommended By
travisnye

   of 13111
 
Provectus Receives Patent Allowance from U.S. Patent and Trademark Office
Provectus Pharmaceuticals Inc.Posted on:05 Jun 13

http://www.pharmiweb.com/pressreleases/ … W_ID=75345

Provectus Pharmaceuticals Inc. (OTCQB:PVCT http://www.pvct.com) a development-stage oncology and dermatology biopharmaceutical company has received allowance from the United States Patent and Trademark Office (USPTO) of its patent application protecting the synthetic process used to produce the small molecule Rose Bengal. A notice of allowance is issued after the USPTO makes a determination that a patent can be granted.

Rose Bengal is the active pharmaceutical ingredient (API) in PV-10 Provectus’s lead oncology drug candidate. The Company’s patent application [no. 12/884833] entitled “Process for the Synthesis of 4567-tetrachloro-3’6’-dihydroxy-2’4’5’7’-tetraiodo-3H-spiro[isobenzofuran-19’-xanthen]-3-one (Rose Bengal) and Related Xanthenes” details a new process for the manufacture of Rose Bengal and related iodinated xanthenes in high purity. The process optimizes conditions to reduce the formation of certain transhalogenated impurities that are present in commercial grade material in accordance with International Conference on Harmonisation (ICH) guidelines for control of impurities in API. The patent allowance provides protection for Rose Bengal API to 2031 and the allowed claims encompass any hypothetical process that controls the amount of transhalogenated impurities in Rose Bengal.

Dr. Craig Dees PhD CEO of Provectus noted “Rose Bengal has had a long and colorful history starting in the 19th century as a humble synthetic wool dye then being used throughout the 20th century as a food dye and in several diagnostic agents. The allowed claims protect our novel synthesis process which is key in manufacturing Rose Bengal to modern quality standards for pharmaceutical use in therapeutic agents. The discovery of a hallmark uncontrolled impurity in material manufactured using conventional processes and our work to eliminate this class of impurities led to the novelty of this allowed application.”

Dr. Dees added “The quality standards established through use of the new process augment the seven year orphan drug exclusivity previously granted for our melanoma and hepatocellular carcinoma indications and significantly strengthen our expanding intellectual property estate around use of Rose Bengal. From a commercial perspective the patent allowance also ensures that Provectus meets pharmaceutical manufacturing standards in important geographical regions worldwide including the United States Australia the EU China India and Japan.”
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News